Summit Therapeutics Share Discussion Threads

[algernon2] 18/9/2016 18:39

It IS low,very low if all goes to plan waterloo.

[waterloo01] 18/9/2016 15:01

I think the Broker target is actually $26 within 12 month, not a long term target. (Thought it was low IF it all works out!)

[waterloo01] 17/9/2016 17:44

We seem to have a few new II holders. Small beer but nice to see AXA added.

[algernon2] 16/9/2016 18:30

"Summit Therapeutics PLC (SMMT) Research Coverage Started at HC Wainwright"



The firm set a “buy” rating and a $26.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 372.73% from the company’s current price.

[chrisatrdg] 16/9/2016 17:06

NASDAQ up again.

On high volume NASDAQ finished up 8.18% hope it continues up next week.

[chrisatrdg] 16/9/2016 11:06

Posting by Free-Money today from the other board(good post).

Trust

Some interesting posts and views from the faithful, both here and on ADFVN.

I don't think Mellon and Buffet made their millions by not sticking to their research while others ran in fear.

It's a very low volume stock right now and a few sells will dip the price of any news driven stock without news.
I am happy with my position and as far as I see the fundamentals of the company haven't changed. We are coming to the end of the current cash runway but we are also in deal negotiations for Ridinilazole.... was that not the plan all along?

I guess it's a matter of trust right now. Do you trust and believe the COE when he says they are not coming back to shareholders for money and they are working on deals and financing through other means. One point worth noting is that the CEO has a major pile of options which require the share price to be above a certain level by March 2017. Any placing around this level now would blow those out of the water… just a thought and remember the board are shareholders too, with many far more invested than us. :-)

I'm happy to hold, wait and see. But the market is made up of all types and is a wonderful mechanism for transferring wealth. Mellon and Buffet seem to have made a success of transferring other people’s money to themselves over the years.

Anyway, just my thoughts as people seem to be getting a bit nervous. GLA

[chrisatrdg] 16/9/2016 09:44

Thanks for your input this morning waterloo01 & I fear we are once again on the edge of a further decline in the share price but with no 'Directors' support.I still believe in the science and you are right we have slipped at least a year which has not helped.I really thought that 2016 was going to be the year but it now looks like 2017 which for me will be my 7th year.

[waterloo01] 16/9/2016 08:58

We wouldn't have been in this position if they had kept to the earlier timetable as we should have had some first read-outs on our phase 2 DMD by now (now mid 2017). Some of this is down to management, although not all. This was one of the key reasons the remuneration committee voted against some of the executive pay (rightly IMV).

As I've mentioned in recent posts, I think the golden goose of a Ridn'azole deal is going through a much longer gestation than hoped for. Apart from not getting (my assumption) any stand out global deal offers, one suspects the BOD are hedging their bets in order to avoid being a one trick pony, or at least avoiding it until we get some indication that Utrophin actually works.

If Utrophin doesn't do what's hoped for, do they still plow on with it, if not then they will still have a valuable asset in C.diff, so not a wipe out and the boys keep their jobs, or at least some do. If Utrophin however shows some effectiveness then it's a different game.

It is all rather binary (as Mellon suggests).

I expected to have been able to at least realise the C.diff asset by now, but like a lot of things, it looks like it's a longer ride to the end.

(Last time we were at 88p, I was told it was a screaming buy and if they were not in a closed period directors would be buying. Guess that window closed as we are yet again in a closed period).

[chrisatrdg] 15/9/2016 22:28

NASDAQ is not at a good place hope will not be reflected on AIM this Friday.

[clarkey26] 15/9/2016 21:43

My gut feel is we could be down to 70-75p at point either a deal or equity raise is announced. I am a fan of the science and a long term holder but I cannot believe we have got into this position. I felt floating on Nasdaq at the time we did was too late and at a biotech high point and seems to have backfired. Glynn better be there confident of a deal or all confidence will be lost. We are in a stronger scientific position than when floated but seem to have got into a much weaker financial position despite it.

[football] 15/9/2016 21:32

down 12.00%

[clarkey26] 15/9/2016 21:12

Umm, not liking the drop on Nasdaq today, volume up as well.

[hugus maximus] 15/9/2016 20:35

On Twitter this afternoon Jim Mellon was asked: "How are you feeling about your Summit investment?" He replied: "It's totally binary. But the other competitors are falling away one by one"

Sarepta seem to have a "rumour" that the FDA are going to grant them approval and their price has gone up to around $30 from around $12 in May after approval was put on hold!

[algernon2] 15/9/2016 17:43

"Summit Therapeutics PLC (NASDAQ: SMMT) Upgraded at Zacks Investment Research.."

[hyper al] 15/9/2016 12:25

Hi waterloo01,

Yep, your scenario sounds reasonable.

Is it a ten bagger from todays SP, because the way things are currently going, we may wish for a 20 bagger in a months time.

I have tons of faith in the research Summit/Oxford undertake, but as is always the case with biotechs the risk is from the lack of investor confidence in the management of the company. Things are certainly at a low on this front and the company really does need to address this problem, maybe they are working on something, if not then what are they doing? an RNS telling us would be nice!

Summit please go out and spend some money on PR, promoting the enormous rewards that could be made by your investors, this PR should be ongoing, not just when funds are required! Yep, i know you would rather spend it on research, but that is not how the market works!

[chrisatrdg] 15/9/2016 10:51

Hi waterloo01

Thanks for your post this morning.I think your scenario is sound and 10 bag is not unreasonable.My only concern is that it is getting very close to the cliff edge and I do not detect from the 'body language' as it were from recent events that we are so near to a deal.However Summit becoming a two shot company is also where I think they will end up hence the 10 bagger.Regards

Edit: I note that the Ask Price is below a £1 - not good & I think will continue if no news.

[waterloo01] 15/9/2016 08:51

Interesting how English reads when it's verbatum!

Reading between the lines, and recovering a little from my disappointment in presentation style, this is now what I think may happen: They will do a deal on c.diff (mix of territories, grants and charity funding) that will fund the phase 3 and leave us with 50% or so of the rights - remembering that Wellcome have between 20%-25% in return for funding to this point. When announced we will then raise enough to see us through till end 2017 (when we get read-outs in DMD), say £25m. If positive then they will raise again to fund the placebo trial.

It will leave us with 100% of DMD and 50% of C.diff and keeping us a two shot company with significant upsides on results through 2017 - 2019 when we might have two drugs on the market. At that point it will either collapse (if trial failures) or 10 bag. Discuss?

[chrisatrdg] 14/9/2016 20:15

A chance to read previous earnings call per link below:

[waterloo01] 14/9/2016 17:13

If there isn't a decent deal on Ridin'zole, or at least not one which delivers enought free cash to fund us for 12 months and IF SRPT does get approval, then it might not get any better timing wise to raise funds, despite our lowly share price (and lack of DMD data read-out).

Certainly the presentations of late don't give me the sense of a company on the cusp of anything transformational in deal terms, which is hugely disappointing, but if they are presenting to potential partners, the way they have presented the last few outings, then it's hardly surprising.

If they are going to present to funds in any raising they had better sharpen up the presentation (hint: More on potential market opportunities, size, relative valuations etc and why it has the potential to make a significant return).

On SRPT, personally I still don't see how SRPT could get approval given the data and suspect some sort of qualified approval at best (or compassionate use at worst?), however the read through to SUMM could be interesting (let alone all other drug companies with questionable data!). If they approve, it should make our path a lot easier, doubly so given our % target population.

[algernon2] 14/9/2016 15:35

Thanks Al.
---------
Too hot where I am.Off swimming.Anyone else find it too hot.
--
Did anyone get to hear the questions at the end of the last discussion or were they dropped from the broadcastfor all listeners?

[hyper al] 14/9/2016 14:33

algernon2

i did'nt know there are two versions of the following

from wikipedia 'Ring a Ring o' Roses'


Common British versions include:

Ring-a-ring o' roses,
A pocket full of posies,
A-tishoo! A-tishoo!
We all fall down.[3]

Common American versions include:

Ring-a-round the rosie,
A pocket full of posies,
Ashes! Ashes!
We all fall down.[3]

The last two lines are sometimes varied to:

Hush! Hush! Hush! Hush!
We've all tumbled down.[3]

--

Lets hope we don't all fall down.

[algernon2] 14/9/2016 13:58

Laugh? I thought I'd never start!

[sorrento06] 14/9/2016 13:28

The silence is deafening!

[algernon2] 14/9/2016 13:15

Could be Pneumonia if he's been hobnobbing with important people!